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Blood brain barrier (BBB) was first discovered by Dr. Paul Enrilich in the late 19th 
century. It is a physiological barrier existing for molecular transportation between the 
blood and the central nervous system (CNS). BBB plays an important role in 
maintaining a homeostatic environment for a healthy and efficient brain and 
protecting the brain from harmful chemicals. However, it is considered to be the main 
obstacle for a large number of drugs to enter the brain. Nanoparticles provide a 
feasible choice as a drug delivery device to cross the BBB because it may overcome 
the biological barrier and increase the bioavailability of the drug in the brain and CNS.  
The aim of this thesis is to develop nanoparticles of biodegradable polymers for drug 
delivery across the blood brain barrier. Emphasis is given to investigate the possible 
effects of the particle surface coating. The work can be divided into two parts. In the 
first part, poly(lactic-co-glycolic acid) (PLGA) nanoparticles were prepared by a 
modified single emulsion solvent evaporation method. Anti-cancer drug paclitaxel or 
fluorescent marker coumarin-6 was encapsulated in the PLGA nanoparticles. PVA 
and Vitamin E TPGS were used as emulsifiers. Tween 80, poloxamer 188 and 
poloxamer 477 were used as coating materials to modify the surface of the 
nanoparticles. Nanoparticles of various recipes were characterized by various state-
of-the art techniques. A model cell line, Madin-Darby Canine Kidney (MDCK) cell 
line, was used to simulate BBB to investigate the feasibility of the nanoparticles to 
cross the blood brain barrier as well as the effects of the surface coating. In vitro 
uptake of fluorescent nanoparticles by MDCK cells was evaluated qualitatively by 
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microreader and quantitatively by confocal laser scanning microscopy. In cellular 
uptake experiments of nanoparticles, it was found that all the nanoparticles can be 
internalized by the MDCK cells to certain extent and the percentage of the cellular 
uptake of the nanoparticles was highly affected by the surface coating. It was thus 
concluded that it is feasible for nanoparticles of biodegradable polymers to deliver 
drugs across the blood brain barrier and the surface coating plays key roles in 
determining the extent of the particles to cross the BBB.  
To further investigate the potential for the nanoparticles to cross the BBB, animal 
testing is important and necessary. The second part of the thesis is thus focused on a 
feasibility investigation for polymeric nanoparticles to deliver contrast materials 
across the BBB for brain image. Gadolinium-DTPA(Gd-DTPA) loaded PLGA or 
poly(Lactic acid)- poly(ethylene glycol) (PLA-PEG) nanoparticles were made by the 
nanoprecipitation and in vivo animal investigation was carried out to evaluate the 
effects of surface coating on magnetic resonance imaging (MRI). It was found that 
PLA-PEG nanoparticles of size less than 100 nm and PLGA nanoparticles of 
diameter less than 200 nm can be manufactured by the nanoprecipitation method. 
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1.1 BLOOD BRAIN BARRIER 
Blood brain barrier (BBB) exists between the blood and the central nervous system 
(CNS), which is a physiological barrier for molecular transportation between the 
blood and the CNS.  It provides neurons with precisely controlled nutritional 
requirements to maintain a proper balance of ions and other chemical constituents and 
isolate the central nervous systems from toxic chemicals in the blood. 
1.1.1 History and Anatomy of Blood Brain Barrier 
It was in the late 19th century that the concept of blood-brain barrier arose. The 
German bacteriologist Paul Ehrlich, the 1908 Nobel Laureate of Medicine and the 
Father of Chemotherapy, observed that certain dyes, e.g., a series of aniline derivates, 
administered intravenously to small animals, stained all the organs except for the 
brain [1]. In subsequent experiments, Edwin E. Goldmann, a student of Ehrlich, 
injected the dye trypan blue directly into the cerebrospinal fluid of rabbits and dogs. 
He found that the dye readily stained the entire brain but did not enter the blood 
stream to stain the other internal organs [2]. The observations drawn from the dye 
studies indicated that the central nervous system is separated from the blood system 
by a barrier of some kind. Lewandowsky, while studying potassium ferrocyannide  
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penetration into the brain, was the first to coin the term blood-brain barrier and called 
it "bluthirnschranke" [3].  
In the 1960s, Reese and Karnovsky [4] and Brightman and Reese [5] repeated the 
Ehrlich/Goldmann experiments at the ultrastructural level by using electron 
microscopy to observe the distribution of the protein tracer horseradish peroxidase 
following intravenous or intrathecal administration. These experiments conclusively 
identified the brain capillary endothelial cell as the site of the brain blood barrier.  
Later experiments demonstrated that the BBB is composed of epithelial tight 
junctions between the plasmalemma of adjacent cells in cerebral capillaries and is 
surrounded by astrocyte foot process [5, 6]. Fig. 1 below shows the diagram of the 
blood brain barrier in detail. The brain capillary is lined with a layer of special 
endothelial cells that lack fenestrations and is sealed with tight junctions.  
 
Fig 1 The blood brain barrier 
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The tight junctions between endothelial cells results in a very high transendothelial 
electrical resistance of 1500-2000 Ω.cm2 compared to 3-33 Ω.cm2 of other tissues 
which reduces the aqueous based paracellular diffusion that is observed in other 
organs [7, 8]. The normal blood brain barrier restricts trans- and paracellular 
movement of blood-born molecules, effectively filtering most ionized, water-soluble 
molecules greater than 180 Daltons in mass [9, 10]. In the case of brain tumor, the 
blood brain barrier is frequently not intact in the center of the malignantly as 
demonstrated by computerized tomography and MR imaging [9]. However, the 
presence of an intact blood brain barrier at the proliferating edge of the tumor has 
been suggested to be one of the major contributing factors to the failure of 
chemotherapy in the treatment of central nervous system neoplasms [11, 12]. 
Comparing brain and general capillaries, brain capillaries are structurally different 
from the blood capillaries in other tissues, which result in the properties of the blood 
brain barrier. Brain capillaries lack the small pores that allow rapid movement of 
solutes from circulation into other organs. In brain capillaries, intercellular cleft, 
pinocytosis, and fenestrae are virtually nonexistent; exchange must pass 
transcellularly. Therefore, only lipid-soluble solutes that can freely diffuse through 
the capillary endothelial membrane may passively cross the BBB. In capillaries of 
other parts of the body, such exchange is overshadowed by other nonspecific 
exchanges. Moreover, there are astrocytes foot processes or limbs that spread out and 
abutting one other, encapsulate the capillaries closely associated with the blood 
vessels to form the BBB. 
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Recent progress in molecular biology revealed that multi-drug efflux pump proteins 
such as P-glycoproteins (p-gp), multidrug resistance protein (MRP) are rich in the 
brain capillaries endothelial cell membrane, which may also play a key role to 
constitute the BBB. These proteins are active transport systems responsible for 
outward transport of a wide range of substances [13]. Both P-gp and MRP are 
membrane proteins belonging to the ABC (ATPbinding cassette) transport protein 
family and can confer multidrug resistance (MDR). They are energy-dependent 
pumps located in the BBB, sharing some functional similarities (somewhat 
overlapping substrate specificities) with broad substrate specificity. Evidence shows 
that P-gp excludes a number of lipophilic compounds from cerebral endothelial cells 
[14]. Many MRP substrates are amphiphilic anions with at least one negatively 
charged group although MRP can also transport cationic and neutral compounds. It 
appears that there are two mechanisms for transport of MRP substrates dependent on 
their ionic nature: direct transport of anionic compounds, whereas, for some cationic 
and neutral compounds the presence of glutathione, likely via cotransport, is required 
[13]. 
1.1.2 Functions of the Blood Brain Barrier  
The main function of the blood brain barrier is to protect the brain. The BBB serves 
as an impermeable wall to prevent the entry of agents from outside of the brain [15]. 
It has been identified that the brain capillary endothelial cell as the physical site of the 
BBB. The continuous tight junctions that seal together the margins of the endothelial 
cells play very important roles in forming the blood brain barrier. Furthermore, in 
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contrast to endothelial cells in many other organs, brain capillary endothelial cells 
contain no direct transendothelial passageways such as fenestrations or channels. 
 
Fig 2  The BBB as an impermeable wall.  
However, the blood brain barrier cannot be absolute. It must facilitate the exchange of 
selected solutes to deliver metabolic substrates and remove metabolic wastes. 
Therefore, the blood brain barrier also serves as a selective sieve [15]. Lipid-soluble 
fuels and waste products, such as O, and CO, can readily cross the lipid bi-layer 
membranes of the endothelial cell and, thus, encounter little difficulty in quickly 
exchanging of metabolic molecules between blood and brain. Polar solutes such as 
glucose and amino acids, however, must depend on other mechanisms to facilitate 
their exchange. This is accomplished by the presence of specific, carrier-mediated 
transport proteins in the luminal and abluminal membranes of the brain capillary 
endothelial cell.   
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 Fig 3  The BBB as a selective sieve.  
With these two functions of the blood brain barrier, the brain capillaries allow the 
passage of oxygen and other essential chemicals and shield the brain from toxins in 
the circulatory system and from biochemical fluctuations and, consequently provide a 
safe environment to the brain.   
1.1.3 Clinical Significance of the Blood Brain Barrier 
Blood brain barrier serves to protect the brain from toxic agents. However, it also 
becomes an insurmountable obstacle for a large number of drugs. Almost all of the 
lipophilic anticancer agents such as doxorubicin [16, 17], epipodophylotoxin and 
vinca alkaloids [18] hardly enter the brain. As a consequence, the therapeutic value of 
many promising drugs is diminished, and brain tumors and other CNS diseases such 
as alzheimer’s disease [19], Parkinson’s disease [20] and HIV infection [21] have 
proved to be most refractory to therapeutic interventions. There are twice as many 
people suffering from central nervous system diseases as those suffering from 
6 
diseases of the blood vessels and heart. However, the world-wide CNS drug market is 
US$33 billion, which is only half of the size for the latter diseases [22]. This is all 
because of the blood brain barrier.  For all these diseases that occur in the central 
nervous systems, the biggest problem is how to overcome the blood brain barrier.  
1.2 METHODS TO OVERCOME THE BLOOD BRAIN BARRIER 
To solve the problems encountered in treatment of brain diseases, a lot of efforts have 
been made and various strategies for enhanced CNS drug delivery have been 
proposed [8, 23-27]. These strategies can be divided into three categories: 
manipulating drugs, disrupting the blood brain barrier and finding alternative routs for 
drug delivery. Drug manipulation includes lipophilic analogs [28], prodrugs [29-31], 
chemical drug delivery [32, 33], carrier-mediated drug delivery [34], and 
receptor/vector mediated drug delivery [35-39]. Disturbing the blood brain barrier 
includes osmotic blood brain barrier disruption [40-44] and biochemical blood brain 
barrier disruption [45-47]. Alternative routes to CNS drug delivery include 
intraventricular/intrathecal route [48], and olfactory pathway [49-51]. Besides these 
methods, there were some direct ways of circumventing the BBB. That is to deliver 
drugs directly to the brain interstitium, which includes injections, catheter, and pumps 
[52, 53]; biodegradable polymer wafers [54, 55], microspheres and nanoparticles; and 
drug delivery from biological tissues [56].  
Table 1 shown below summarizes the technical approaches, their advantages and 
limitations.  
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Table 1 Drug delivery to CNS: Technical approaches, advantages and limitations 
[19]. 
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All the methods ment limited 
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1.3 PARTI HE B
BA
rticles, drugs can be released at right rate and dose at specific 
sites in body during a certain time to realize the accurate delivery which will enhance 
The potential advantages of nanoparticles for drug delivery across the BBB include 
1. Nanoparticle system can deliver a relatively more concentrated drug dose to the 
brain, compared to that for the prodrug or drug-vector approach, reducing the needed 
dose and thus the drug-associated side effects; 
ioned above have advantages and factors. Among these 
NANO
RRIER  
CLES TO CROSS T LOOD BRAIN 
Nanoparticles  are solid colloidal particles ranging in size from 10 to 1000 nm, in 
which therapeutic drugs can be adsorbed, entrapped, or covalently attached [57]. 
Formulated by nanopa
the therapeutic efficacy and reduce the side effects.  
[58]:  
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2. Nanoparticles of small enough size may have ability to transport through the tight 
junction (knealing between endothelial cells, paracelluar transportation); 
6. Nanoparticle formulation is a platform technology, which can be applicable to a 
7. Nanoparticles of small enough size and appropriate coating may have ability to 
1.4 RESEARCH OBJECTIVES 
g nanoparticles to deliver 
across the BBB therapeutic agents for chemotherapy and contrast materials for 
orbate 
tide delivery across the 
BBB, this kind of nanoparticles has its disadvantages. Firstly, this polymer is not 
3. Nanoparticles are capable of bypassing the P-gp efflux system. Nanoparticles may 
be equipped with a mask (surface coating) to the p-gp to bring the drug molecules 
across the BBB; 
4. Nanoparticles may offer protection for the activity of the drug molecules during 
transportation in the circulation, across the BBB and in the brain; 
5. Nanoparticles may provide sustained release of drug in the brain to prolong the 
pharmacological action of drug molecules; 
wide range of drugs, either hydrophilic or lipophilic. 
escape from the elimination by the RES to realize long-circulating properties,  
Until now, only a few papers have been published on usin
medical imaging of the brain. However, most of them were focused on using 
poly(butylcyanoacrylate) (PBCA) nanoparticles with surface coating of polys
80. Despite the success of PBCA nanoparticles for drug/pep
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authorized to application in human (not FDA-approved). Secondly, there have been 
reports of in vivo toxicity of PBCA-polysorbate 80 nanoparticles. Olivier et al 
reported that PBCA nanoparticle caused mortality (3 to 4 out of 10 mice) and 
dramatically decreased locomotor activity in mice dosed with dalargin loaded PBCA 
nanoparticles, but not with non biodegradable polystyrene nanoparticles (the latter did 
not show any CNS penetration of dalargin) [59]. It was concluded by the researchers 
that a non specific permeabilization of the BBB, probably related to the toxicity of the 
carrier, may account for the CNS penetration of dalargin associated with PBCA 
nanoparticles and polysorbate 80. Considering the in vivo toxicity reported on the 
PBCA nanoparticle system, FDA-approved biodegradable polymers such as PLGA 
and PLA-PEG were used in this project. Our main objective is to developed an 
appropriate nanoparticle technology to make PLGA and PLA-PEG nanoparticles of 
small enough size and appropriate surface coating to deliver therapeutic agents and 
contrast materials across the blood brain barrier for chemotherapy and medical 
imaging of the brain, respectively. The project can be divided into two parts. In the 
first part, paclitaxel loaded PLGA nanoparticles will be prepared by a modified single 
emulsion method and characterized by various state-of-the art techniques. In vitro 
evaluation of such nanoparticles to cross the blood brain barrier will be investigated 
by employing MDCK cell line as an in vitro model of the BBB. The effects of the 
surface coating will be studied. In the second parts, gadolinium-DTPA loaded PLGA 
and PEG-PLA nanoparticles will be prepared by the nanoprecipitation method, which 
will be injected in animals for in vivo magnetic resonance imaging (MRI).  
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1.4.1 In Vitro Evaluation of PLGA Nanoparticles for Paclitaxel Delivery Across 
the Blood Brain Barrier 
PLGA is used in this research because of its biodegradability and biocompatibility. It 
is approved by US Food and Drug Agency (FDA). PLGA nanoparticles were usually 
prepared in the literature by single emulsion solvent evaporation method with 
 washing, a fraction of PVA may always remain on the 
nanoparticle surface because PVA forms an interconnected network with the polymer 
at the interface [61]. The residual PVA associated with PLGA nanoparticles may 
have side effects and affect the physical properties and cellular uptake of the 
nanoparticles. To reduce or remove the negative effects of the residual PVA, surface 
modification of the particles will be carried out by surface coating or replacing the 
PVA emulsifier by a natural emulsifier such as phopspholipid or PEGylated vitamin 
E 9full name, or Vitamin E-TPGS or TPGS). Three coating materials, Tween 80, 
poloxamer 188 and poloxamer 407 will be used in the study. These materials are all 
ampiphilic polymers and may change the hydrophobicity of the particle surface. 
Tween 80 has been reported to be useful for overcoming the blood brain barrier with 
PBCA nanoparticles [62, 63-65]. Poloxamers have been reported to help the particles 
prolong the time in the blood stream by forming a steric stabilizing layer of PEG on 
the surface of the particle [66, 67]. TPGS has shown to be an effective emulsifier 
which can achieve high drug encapsulation efficiency, size and size distribution, 
morphological and physicochemical properties, desired in vitro release kinetics of the 
nanoparticles, and high cellular uptake of nanoparticles [68-71]. In this study the 
polyvinyl alcohol (PVA), a commercial macromolecule product as the emulsifier [60]. 
However, despite repeated
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effects of all these surfactants on the feasibility of nanoparticles to penetrate the blood 
brain barrier will be investigated. 
Paclitaxel (Taxol®) is one of the most potent antitumor agents and has been 
apptroved by FDA for treatment of a wide spectrum of cancers, especially breast 
cancer, ovarian cancer, small cell and non small cell lung cancer [72-76]. It has also 
been used to treat malignant glioma and brain metastases [77-79]. However, brain 
tumors constitute a difficult problem and the therapeutic benefit of paclitaxel has been 
limited. This could be attributed to delivery problem to cross the BBB. Although 
In this study, paclitaxel loaded PLGA nanoparticles will be prepared by single 
emulsion solvent evaporation method. Madin-Darby canine kidney (MDCK) cell line 
will be used as an in vitro model of the BBB. MDCK is a kidney epithelial cell line, 
which forms a tight monolayer similar to that of the brain endothelial cell monolayer. 
MDCK cells display morphological and enzymatic characteristics also found in the 
brain endothelial cells (e.g., acetylcholinesterase, butyryl-cholinesterase, gamma-
glutamyl transpeptidase). MDCK monolayer represents a relatively simple model for 
paclitaxel is very lipophilic, concentrations in the CNS were found very low after 
intravenous administration [80, 81]. It was demonstrated that the p-gp blocker 
valspodar enhances paclitaxel entry into the brains of mice after intravenous dosing 
and that valspodar dramatically increases paclitaxel effectiveness against a human 
glioblastoma implanted into the CNS of nude mice [82]. These represent the 
preliminary data directly demonstrating the role of p-gp in limiting the therapeutic 
availability of paclitaxel to the CNS.  
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the screening of compounds that are transported passively across the blood-brain 
barrier.    
To further evaluate the potential of nanoparticles of biodegradable polymers to 
penetrate the BBB, animal study is important and necessary. Radiology agent was 
usually used to label the nanoparticles in the literature. However, it is not safe. In our 
study, Gd-
1.4.2 Gd-DTPA Loaded Nanoparticles of Biodegradable Polymers for MRI of 
the Brain 
DTPA loaded nanoparticles will be prepared to facilitate the visualization 
of the particles administered in rats. Gd-DTPA is a widely used, commercially 
available MRI contrast agent. MR imaging is a imaging method using a strong 
magnetic field and gradient fields to localize bursts of radiofrequency signals coming 
 
from a system of spins consisting of reorienting hydrogen H nuclei after they have 
been disturbed by radiofrequency RF pulses. It can produces detailed pictures of the 
brain. Thus, in vivo study on nanoparticles to cross the blood brain barrier can be 
carried out by injecting Gd-DTPA loaded nanoparticles intravenously to the animal 
and then detect the distribution of the nanoparticle by MR. Our objective is to prepare 
Gd-DTPA loaded PLGA and PEG-PLA nanoparticles by the nanoprecipitation 
method and investigate its in vivo image of the animal brain by MRI. Particle size, 
surface charge, agent encapsulation efficiency and in vitro release of Gd-DTPA will 
also be studied and compared among nanoparticles of various biodegradable 
polymer/copolymers to pursue a best nanoparticle formulation.  
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1.5 THESIS ORGANIZATION 
This thesis is made up of five chapters. Chapter One gives a general introduction of 
the project. It comprises of introduction and clinical significance of the blood brain 
barrier, a review of various methods to overcome the blood brain barrier, the 
possibility of nanoparticles of biodegradable polymers to cross the blood brain barrier, 
as well as the objective of this project. Chapter Two is a collection of summarized 
formation on cancer, chemotherapy, drug delivery, and nanoparticles of 
e various materials and methods used in 









biodegradable polymers. In Chapter Three th
in Chapter Four. Finally, the conclusions drawn from the project and the future work 






2.1 CANCER, CHEMOTHERAPY, AND CONTROLLED DRUG 
DELIVERY 
Cancer is any malignant growth or tumor caused by abnormal and uncontrolled cell 
division; it may spread to other parts of the body through the lymphatic system or the 
blood system [83]. There are more than 10 million people diagnosed with cancer 
every year. Cancer causes 6 million deaths every year— or 12% of deaths worldwide 
[84]. It is estimated that there will be 15 million new cases every year by 2020. In the 
United States of America, a quarter of all deaths are due to cancer. It was estimated 
that 203.1 per 100,000 persons were died of cancer in 1997 and that there were totally 
1,334,100 new cancer cases and 556,500 deaths in 2003 [85]. In China, cancer has 
been the first and second cause of death in urban area (23.89% of total deaths) and 
rural areas (18.40% of total deaths), respectively [86]. In Singapore, cancer continued 
to be the leading cause of death in 2001, accounting for 28.2 percent of all deaths [87].  
The objectives of cancer treatment are to cure the patients if possible, prolong their 
life, and improve the quality of their life. Treatment of cancer may involve surgery, 
radiation therapy, chemotherapy, biotherapy, bone marrow transplant, or some 
combination of these [88]. Usually surgery is the first treatment for cancers. However, 
it is difficult for surgical removal of solid tumor to be thorough and it is not 
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applicable for some cases such as leukemia. It is estimated that more than half of 
cancer patients receive systemic chemotherapy as part of their treatment [88].  
Chemotherapy, at the first point, is to employ chemicals in treatment of diseases. It 
can be defined as “curing by chemicals” [89, 90]. In chemotherapy, drugs are 
normally given in cycles, most commonly three to four weeks apart, in a period of 
four to six months. Between cycles, the normal cells (blue line) recover but the tumor 
cells (red line) do not (see figure below). Over the entire course it’s hoped that the 
tumor cells would have been destroyed, leaving the body a little battered but intact.  
 
Fig 4 Chemotherapy cycles 
The disadvantage of chemotherapy is that normal cells can also be harmed by the 
anticancer drugs, especially those cells that normally divide quickly. These include 
cells in the hari flooicles, bone marrow, and lining of the gastrointestinal tract. The 
results can be hair loss; depressed red and white blood cell counts, causing anemia 
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and an inability to fight off infections, respectively; and nausea, vomiting and mouth 
sores. Chemotherapy can also have several neurological side effects, such as fuzzy 
thinking and difficulty concentrating [91]. 
Controlled drug delivery systems provide an alternative to the traditional 
chemotherapy, which have several advantages. Controlled drug delivery occurs when 
a polymer, whether natural or synthetic, is judiciously combined with a drug or other 
active agent in such a way that the active agent is released from the material in a pre-
designed manner [92]. Firstly, controlled drug delivery systems can improve the 
efficacy of the drug. Secondly, it can reduce toxicity of the cancer drug and side 
effects of drug adjuvant [93]. Thirdly, it can provide a sustained and effective drug 
level by controlled release of the drug (Fig. 5). Last but not least, it can improve 
patient compliance and convenience.  
 
Fig 5 Drug levels in the blood with (Left) traditional drug dosing and (Right) 
controlled delivery dosing  
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2.2 BRAIN CANCER AND OTHER BRAIN DISEASES 
A brain tumor is a mass of unnecessary cells growing in the brain [94]. There are two 
basic kinds of brain tumors: primary brain tumors and metastatic brain tumors [95]. 
Primary brain tumors start, and tend to stay, in the brain. metastatic brain tumors 
begin as cancer elsewhere in the body and spreads to the brain. Primary brain tumors 
occur in people of all ages, but they are statistically more frequent in two age groups, 
children under the age of 15 and older adults. Metastatic brain tumors are much more 
common in adults. An estimated 40,900 new cases of primary brain tumors are 
expected to be diagnosed in 2004. This is based on an incidence rate of 14 per 
100,000 persons and a projected 2004 U.S. population of 285,266,000. The incidence 
statistics stated above include those with all primary brain tumors, both malignant and 
benign, and are based on the year 2004 population. In the United States, 
approximately 3,140 children younger than age 20 are diagnosed annually with 
primary brain tumors. Brain tumors are the most common of the solid tumors in 
children, and the second most frequent malignancy of childhood. Although statistics 
for brain metastases are not readily available, it is estimated that over 100,000 cancer 
patients per year will have symptoms due to metastatic train tumors and up to 80,000 
per year will have a metastatic tumor in the spinal cord [96].  
Surgery is the chief form of treatment for brain tumors that lie within the membranes 
covering the brain or in parts of the brain that can be removed without damaging 
critical neurological functions [97]. Because a tumor will recur if any tumor cells are 
left behind, the surgeon’s goal is to remove the entire tumor whenever possible. 
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Radiation therapy and chemotherapy, in general, are used as secondary or adjuvant 
treatment for tumors that cannot be cured by surgery alone. Chemotherapy works to 
destroy tumor cells with drugs that may be given either alone or in combination with 
other treatments [97]. 
2.3 NANOPARTICLE TECHNOLOGY 
2.3.1 Introduction of Nanoparticles 
Nanoparticles  are solid colloidal particles ranging in size from 10 to 1000 nm.  
Nanoparticles can serve as a novel drug delivery carriers to tissues throughout the 
body. This is accomplished by masking the membrane barrier, limiting characteristics 
of the therapeutic drug molecules, as well as retaining drug stability, with that of the 
properties of the coloidal drug carrier. Once the nanoparticles reach the desired tissue, 
release of the drug may occur by desopption, diffusion through the nanoparticles 
matrix or polymer wall or nanoparticles erosion, or some combination of any or all 
mechanisms.  
The nanometer size-ranges of the drug delivery systems offer certain distinct 
advantages for drug delivery due to their sub-cellular and sub-micron size, 
nanoparticles can penetrate deep into tissues through fine capillaries, cross the 
genestration present in the epithelial lining, and are generally taken up effciently by 
the cells [98]. Nanoparticles have in general relatively high intracellular uptake 
compared to microparticles. Previous studies show that particle size significantly 
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affects celllar and tissue uptake, and in some cell lines, only the submicron size 
particles are taken up efficienyly but not the larger size microparticles [99] 
2.3.2 Fabrication Techniques of Nanoparticles 
Nanoparticles can be fabricated in different ways according to the polymers used and 
the properties of the drugs. Generally, they can be divided into two catalogues, 
dispersion of performed polymers and polymerization methods. 
2.3.2.1 Dispersion of performed polymers 
Solvent evaporation method [100]  
In this method, the polymer is dissolved in an organic solvent. The drug is dissolved 
or dispersed into the performed polymer solution, and this mixture is then emulsified 
into an aqueous solution to make an oil (O) in water (W) emulsion by using a 
surfactant/emulsifying agent like poly (vinyl alcohol), polysorbate-80, poloxamer-188, 
etc. After the formation of a stable emulsion, the organic solvent is evaporated by 
increasing the temperature/under pressure or by continuous stirring. 
Spontaneous emulsification/ solvent diffusion method [101]  
This method is a modified version of the solvent evaporation method. Briefly, the 
water-soluble solvent along with the water insoluble organic solvent was used as an 
oil phase. Due to the spontaneous diffusion of water-soluble solvent, an interfacial 
turbulence is created between two phases leading to the formation of smaller particles. 
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As the concentration of water-soluble solvent (acetone) increases, a considerable 
decrease in particle size can be achieved. 
Salting out/ emulsification-diffusion method  
Salting-Out [102] 
In this method, polymer and drug are dissolved in acetone.  The solution is then 
emulsified under vigorous mechanical stirring in an aqueous gel containing the 
salting-out agent and a colloidal stabilizer.  This oil-in-water emulsion is diluted with 
a sufficient volume of water or aqueous solutions to enhance the diffusion of acetone 
into the aqueous phase, thus inducing the formation of nanoparticles.  The remaining 
solvent and salting-out agent are eliminated by cross-flow filtration.  
Emulsification-Diffusion [103] 
 
This method can be considered as a modification of the salting-out procedure, 
avoiding the use of salts and hence intensive purification steps.  It involves the use of 
a partially water-soluble solvent, which is previously saturated in water to ensure the 
initial thermodynamic equilibrium of both liquids.  The polymer is dissolved in the 
water-saturated solvent, and this organic phase is emulsified, under vigorous agitation, 
in an aqueous solution containing a stabilizer.  The subsequent addition of water to 
the system causes the solvent to diffuse into the external phase, resulting in the 
formation of nanoparticles.   
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Supercritical fluid technology [104] 
In the rapid expansion of supercritical solution (RESS) method the solute of interest 
is solubilized in a supercritical fluid and the solution is expanded through a nozzle. 
Thus, the solvent power of supercritical fluid dramatically decreases and the solute 
eventually precipitates. 
2.3.2.2 Polymerization methods 
Emulsion polymerization [105] 
Emulsion polymerization characterizes both radical and anionic polymerization. The 
process consists of building a chain of polymers, which acts as the drug carrier, from 
single monomer units of a given compound. Polymerization occurs spontaneously at 
room temperature after initiation by either free radical of ion formation. Triggers for 
polymer growth include high-energy radiation, UV light, or hydroxyl ions. Once 
polymerization is complete, the solution is filtered and neutralized to remove any 
residual monomers. The polymers forms micelles and droplets (nanoparticles), 
consisting of approximately 100 to 107 polymer molecules. The mass of polymers 
inherent in this type of nanoparticle formulation provides the available space that acts 
as a carrier for adsorption or absorption of the drug.  
Emulsion polymerization can also be accomplished in an organic phase rather than an 
aqueous phase. This process has been adapted for use with polyakyl-cyanoacrylate 
nanoparticles. 
24 
Interfacial polymerization [106] 
Interfacial polymerization is similar to emulsion polymerization in that monomers are 
used to create polymers. However, the mechanism is different. Interfacial 
polymerization occurs when an aqueous and organic phase are brought together by 
homogenization, emulsification, or micro-fluidization under high-torque mechanical 
stirring. This precludes the inclusion of peptide/proteins at this step secondary to 
mechanical shearing.  
A subset of interfacial polymerization is the process of adding a solvent mixture of 
benzyl benzoate, acetone, and phospholipids to the organic phase containing the drug 
and monomer. It has been suggested that this process entourages the formation of the 
nanocapsule shell between the aqueous phase and the benzyl benzoate drops in the 
organic phase. One advantage of interfacial polymerization may be the encapsulation 
of the drug. Once the drug is encapsulated, it is protected until it reaches the target 
tissue and degradation occurs. In the case of CNS delivery, it is desirable to protect or 
disguise the drug until it is past the barrier and can be released into the brain. 
2.4  BIODEGRADABLE POLYMERS FOR CONTROLLED DRUG 
DELIVERY  
2.4.1 Biodegradable Polymers in Drug Delivery Systems 
Biodegradable polymers are widely used in controlled drug delivery systems because 
they can be expelled by human body and cause no harm to human. The biodegradable 
polymers in drug delivery can be divided into two categories: natural biodegradable 
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polymers and synthetic biodegradable polymers. Natural biodegradable polymers like 
bovine serum albumin (BSA), human serum albumin (HSA), collagen, gelatin, 
hemoglobin have been studied. However, the use of them is limited due to their 
higher costs and questionable purity. Since last two decades, synthetic biodegradable 
polymers have been increasingly used to deliver drugs, since they are free from most 
of the problems associated with the natural polymers. Poly (amides), poly (amino 
acids), poly (alkyl-α-cyano acrylates), poly (esters), poly (orthoresters), poly 
(urethanes), and poly (acrylamides) have been used to prepare various drug loaded 
devices. Table 1 below show the structures of some biodegradable polymers 
mentioned here. 






Plasma expander used as polymer-drug conjugate 
for distribution control. [107] Enzyme cleavable 
side chains employed to target release at colon 
[108]. Hydrolytically degradable hydrogels 
produced by crosslinking with N, O-dimethacryloyl 
hydroxylamine linker [109]. 








inhibit drug release by diffusion mechanisms and 
allow drug release only after the hydrolysis of the 
polymer chains at the surface of the device [111] 
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Hard and soft segment polymers containing PEG 
for temporal controlled release [112, 113]. 
Azo-containing polymers used to control site of 
polymer-drug conjugate degradation [114]. 
Anti-infectious biomaterials containing antibiotics 
[115]. 
  





copolymer: Poly(lactic acid-co-glycolic acid) 
(PLGA) 
 
Biosynthetic poly(ester) often employed as 
copolymer with hydroxyvalerate monomer. 
Among the biodegradable polymers, the thermoplastic aliphatic poly (esters) like 
PLA, PGA and especially their copolymer PLGA have generated tremendous interest 
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due to their excellent biocompatibility and biodegradability. They are widely used in 
the nanoparticulate drug delivery systems.  
2.4.2 Poly (lactide-co-glycolide) (PLGA)  
Poly (lactide-co-glycolide) (PLGA) is the best characterized and most widely studied 
biodegradable polymer. Moreover, it is a FDA approved material. It is especially 
widely used in the form of microspheres and nanoparticles as controlled drug delivery 
systems.  
PLGA is the copolymer of PLA and PGA. The structure of these two polymers can be 
found in table 3. They are both poly (ester). The polymer PLA can exist in an 
optically active stereoregular form (L-PLA) and in an optically inactive racemic form 
(D, L-PLA). L-PLA is found to be semicrystalline in nature due to high regularity of 
its polymer chain while D, L-PLA is an amorphous polymer because of irregularities 
in its polymer chain structure. Hence, D, L-PLA is more used than L-PLA since it 
enables more homogeneous dispersion of the drug in the polymer matrix. PGA is 
highly crystalline because it lacks the methyl side groups of the PLA. Lactic acid is 
more hydrophobic than glycolic acid. Thus lactide-rich PLGA copolymers are less 
hydrophilic, absorb less water, and degrade more slowly. 
By varying the monomer ratios in the polymer processing and by varying the 
processing conditions, the resulting polymer can exhibit drug release capabilities for 
months or even years.  
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 Both, in vitro and in vivo the PLGA copolymer undergoes degradation in an aqueous 
environment (hydrolytic degradation or biodegradation) through cleavage of its 
backbone ester linkages. The polymer chains undergo bulk degradation and the 
degradation occurs at uniform rate throughout the PLGA matrix. It has been reported 
that the PLGA biodegradation occurs through random hydrolytic chain scissions of 
the swollen polymer. The carboxylic end groups present in the PLGA chains increase 
in number during the biodegradation process as the individual polymer chains are 
cleaved; these are known to catalyze the biodegradation process. The biodegradation 
rate of the PLGA copolymers are dependent on the molar ratio of the lactic and 
glycolic acids in the polymer chain, molecular weight of the polymer, the degree of 
the crystallinity, and the Tg of the polymer [116].  
The PLGA polymer degrades into lactic and glycolic acids. Lactic acid enters the 
tricarboxylic acid cycle and is metabolized and subsequently eliminated from the 
body as carbon dioxide and water. In a study conducted using 14C-labeled PLA 
implant, it was concluded that lactic acid is eliminated through respiration as carbon 
dioxide. Glycolic acid is either excreted unchanged in the kidney or it enters the 
tricarboxylic acid cycle and eventually eliminated as carbon dioxide and water. 
The drug entrapped in PLGA matrix is released at a sustained rate through diffusion 
of the drug in the polymer matrix and by degradation of the polymer matrix.  
2.4.3 Poly (Lactic acid) – poly (ethylene glycol) (PLA-PEG) Copolymers 
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PLA-PEG copolymers and their use as an effective biomaterial in drug delivery and 
tissue engineering have been well characterized [117-123]. PLA is the backbone of 
the polymer. Polyethylene glycol (PEG) is widely used to cloak the particles and 
obtain stealthy properties. With one end being adsorbed on or attached to the particles 
surface, PEG chain extrudes outwards to form hydrophilic and flexible 
‘‘conformational clouds’’, which become an effective protective layer to inhibit the 
opsonization [124-127].  
2.5 NANOPARTICLES OF BIODEGRADABLE POLYMERS TO 
PENETRATE THE BLOOD BRAIN BARRIER 
2.5.1 Ideal Properties of Nanoparticles across the Blood Brain Barrier 
There have been intensive investigations focused on nanoparticles for drug delivery 
across the BBB. Jorg Kreuter is the first one who successfully developed polysorbate-
coated polybutylcyanoacrylate nanoparticles to deliver an analgesic drug dalargin into 
the brain [63]. Maltodextrin [128], stearic acid [129], and Emulsifying Wax & Brij 78 
[130] particles had also been investigated for drug delivery across the blood brain 
barrier.   
As mentioned in the methods to penetrate the blood brain barrier, nanoparticles of 
biodegradable polymers may be a promising strategy to overcome the blood brain 
barrier. In P.R. Lockman’s paper [20], the ideal properties of nanoparticle based drug 
delivery system for drug delivery across the blood brain barrier were discussed. Table 
3 shows a list of ideal propertis of polymeric-based nanoparticles for drug delivery to 
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cross the blood brain barrier. However, these are only general ideal properties for the 
nanoparticles. When the particles are used for a certain drug or agent, the properties 
of the drug or agent must also be considered as the encapsulation efficiency of the 
nanoparticles to the drug are also very important, especially for some expensive drugs. 
Table 3 Ideal properties of polymeric-based nanoparticles for drug delivery across 
the BBB [20] 






Particle Diameter < 100nm 
Stable in blood (i.e., no opsonization by proteins) 
BBB-targeted (i.e., use of cell surface ligands, receptor-mediated endocytosis) 
No activation of neutrophils 
No platelet aggregation 
Avoidance of the reticuloendothelial system 
Noninflammatory 
Prolonged circulation time 
Scalable and cost-effective with regard to manufacturing process 
Amenable to small molecules, peptides, proteins, or muclei acids 
2.5.2 Possible Mechanism of Nanoparticles to Penetrate the Blood Brain Barrier 
To date, the exact transport mechanisms of nanoparticle across the BBB are not fully 
understood. Kreuter and colleagues proposed the following possible mechanisms for 
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nanoparticle mediated drug uptake by the brain which could contribute alone or in 
combination [63]: 
1. Enhanced retention of nanoparticles in the brain blood capillaries with an 
adsorption to the capillary wall. This leads to the creation of a high 
concentration gradient that enhances transport across the BBB. 
2. Surfactant effect produced by the polysorbate coating resulted in the 
solubilisation of endothelia cell membrane lipids and membrane fluidization, 
thus enhanced the penetration of drug through the BBB. 
3. The presence of nanoparticles leads to an opening of the tight junction 
between the endothelial cells. The drug could permeate through in free form 
or together with the nanoparticles in bound form. 
4. Polysorbate 80 coating facilitates nanoparticles interaction with the BBB 
endothelial cells, leading to endocytosis of nanoparticles followed by the 
release of the drug within these cells and delivery to the brain. 
5. Nanoparticles with bound drug could be transcytosed through the endothelia 
cell layer. 
6. Polysorbate 80, as the coating agent, could inhibit the efflux system, 
especially P-gp. 
The mechanism of the nanoparticle-mediated transport of the drugs across the blood-
brain barrier at present is not fully understood yet. Several possible routs has been 
summarized which include paracellular pathway, transcelluar pathway, transport, 
specific endocytosis and adsorptive endocytosis. Considering the property of the 
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nanoparticles, it is easy to find that the possibility of the first three pathways is very 
low. The most likely mechanism for nanoparticles to cross the blood brain barrier is 
endocytosis by the endothelial cells lining the brain blood capillaries.  
As seen in Kreuter’s publications [62], nanoparticle-mediated drug transport to the 
brain depends on the over-coating of the particles with polysorbates, especially 
polysorbate 80. It was proposed that over-coating with these materials seems to lead 
to the adsorption of apolipoprotein E from blood plasma onto the nanoparticle surface. 
The particles then seem to mimic low density lipoprotein particles and could interact 
with the LDL receptor leading to their uptake by the endothelial cells. After this the 
drug may be released in these cells and deffuse into the brain interior or the particles 
may be transcytosed. Other processes such as tight junction modulation of P-
glycoprotein inhibition also may occur. These mechanisms may run in parallel or may 
be cooperative thus enabling a drug delivery to the brain. From the possible 
mechanism of nanoparticles to penetrate the blood brain barrier, it can be seen that 
surface modification of the nanoparticles may be very important.  
2.5.3 Surface Modification of Nanoparticles 
To penetrate the blood-brain barrier, the surface properties of the nanoparticles are 
very important. It is because the hydrophobicity is one of the important factors that 
determine the passive diffusion of substances across the brain endothelial cells. 
Furthermore, as mentioned in the previous part, surface coating of the nanoparticles 
may lead to specific endocytosis.  
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In J. Kreuter et. al. ’s study, the ability of 12 different surfactants, (Polysorbate 20, 40, 
60, 80, Polyoxyethylene-(23)-laurylether (Brij® 35), Poloxamers 184, 188, 338, 407, 
Poloxamine 908, Cremophor® EZ, RH 40), coated onto the surface of nanoparticles, 
to facilitate the delivery of a nanoparticles-bound model drug, dalargin, was 
investigated [62]. The leu-enkephalin analogue hexapeptide dalargin was bound to 
polybutylcyanoacrylate nanoparticles by sorption for 3 h. Different surfactant were 
then coated over these nanoparticles and were injected intravenously into mice. 
Nociceptive analgesia was then measured by the tail-flick text 15, 30, 45 and 90 min 
after injection. Only nanoparticles that had been boated with polysorbate 20, 40, 60 
and 80 yielded a significant effect. The highest effect was observed with polysorbate. 
Maximum effects were found after 15 min, at a dalargin dosage of 10 mg/kg, and 
after 45 min, with 7.5 mg/kg.  
2.6 MRI AND MRI CONTRAST MEDIUM 
MR imaging is a imaging method using a strong magnetic field and gradient fields to 
localize bursts of radiofrequency signals coming from a system of spins consisting of 
reorienting hydrogen H nuclei after they have been disturbed by radiofrequency RF 
pulses. MR imaging produces high resolution, high contrast two-dimensional image 
slices of arbitrary orientation, but it is also a true volume imaging technique and 
three-dimensional volumes can be measured directly. Applications of MR imaging 
have steadily widened over the last decade. Currently it is the preferred cross-
sectional imaging modality in most diseases of the brain and spine and has attained 
major importance in imaging diseases of the musculoskeletal system. MR imaging in 
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the head and neck and pelvis has attained a substantial level of clinical use, and its 
applications in the abdomen, kidneys and chest are rapidly increasing with the advent 
of ultrafast MR imaging techniques.  
Contrast medium is various agents used to facilitate distinction between structures on 
images as a consequence of differences in contrast. MR contrast media either act 
predominantly on T1 relaxation which results in signal enhancement and "positive" 
contrast, or on T2 relaxation, which results in signal reduction and "negative" contrast.  
The positive contrast agents are typically small molecular weight compounds 
containing as their active element Gadolinium Gd , Manganese Mn or Iron Fe , all of 
which have unpaired electron spins in their outer shells and long relaxivities which 
make them good T1 relaxation agents 
Diethylenetriaminepentaacetic acid gadolinium(III) dihydrogen salt hydrate (Gd-
DTPA) (C14H20GdN3O10 · xH2O 547.57) is widely used metal ion complex for 
MRI used in the diagnosis of cerebral tumors, CNS diseases, hepatic tumors, pituitary 
adenomas, multiple sclerosis, and blood-brain barrier impairment. 
 
Fig. 6 Chemical structure of Gd-DTPA 
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CHAPTER THREE 
MATERIALS AND METHODS 
3.1 MATERIALS 
Poly (D,L-lactide-co-glycolide) (PLGA, 50:50, MW 40000-75000), polyvinyl alcohol 
(PVA MW 30000-70000), were purchased from Sigma chemical Co. USA. Paclitaxel 
was purchased from Dabur India Limited, India and Hande Biotechnology Inc., China. 
Tween 80 was purchased from ICN biomedical company. Vitamin E succinate with 
polyethylene glycol 1000 (Vitamin E TPGS) was provided by Eastman Chemical 
Company (USA). F68 and F127 were provided by BASF. Cormarin -6 was purchased 
from Aldrich Chem. Co. The solvent dichloromethane (DCM, analytical grade) was 
purchased from Mallinckrodt. Acetonitrile for HPLC/ Spectro use (FW=41.05) was 
purchased from Tedia. Madin-Darby canine kidney (MDCK) epithelial cell line was 
phased from American Type Culture Collection (CCL-34) and passages 58-70 were 
used. Hank’s balanced salt solution (HBSS), Penicillin Streptomycin, Dulbecco's 
Modification of Eagle's Medium (DMEM), and PBS were purchased from sigma. 
Fetal calf serum was purchased from Hyclone.  Fm4-64 was phased from molecular 
probes. Triton 100 was purchased from BDH limited Poole England. Deionized water 
produced by Millipore (Millipore Corporation, Bedford, MX 01730, USA) was used 
throughout. Gadolinium-DTPA was purchased from Sigma. PLA-PEG was provided 




3.2.1 In Vitro Evaluation of PLGA Nanoparticles for Paclitaxel Delivery Across 
the Blood Brain Barrier  
3.2.1.1 Fabrication of nanoparticles 
PLGA nanoparticles were prepared by the single emulsion solvent evaporation 
method. Briefly, 110 mg PLGA and 5.5 mg paclitaxel were dissolved in 8 ml DCM to 
form the organic phase. The organic phase was poured slowly into 120 ml water with 
0.6g PVA or 36mg VE-TPGS. The mixture was then sonicated for 120 seconds and 
the resultant emulsion was stirred overnight with a magnetic stirrer to allow for the 
evaporation of the organic solvent. The nanoparticles were collected by centrifugation 
at 11200 rpm for 15 min. Then the particles were washed with distilled water for 
three times by centrifugation to remove the excess emulsifier. The naked 
nanoparticles were then incubated in the solutions of 0.5% (w/v) coating materials for 
three hours and washed by centrifugation for three times again. Finally, the products 
were freeze dried to obtain fine powders, which was kept in vacuum desiccator for 
future use.  
The fluorescence nanoparticles were prepared using the same method while 
cormorin-6 was used as a fluorescence marker instead of paclitaxel.   
3.2.1.2 Nanoparticles characterizations 
Size and size distribution 
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The particle size and size distribution of the nanoparticles were measured by the laser 
light scattering (Brookhaven Instruments Corporation 90 plus Particle Sizer) at 25ºC 
and at a scattering angle of 90º. The dried nanoparticles were suspended in deionised 
water by sonication and determined for the volume mean diameter, size distribution 
and polydispersity.  
Zeta potential 
Zeta potential was measured by the laser Doppler anemometry (Zeta Plus, Zeta 
potential Analyzer, Brookhaven Instruments Corporation). The particle was re-
suspended in deionized water before measurement. The value was recorded as the 
average of five measurements.   
Morphology 
Scanning electrical microscopy (SEM) and atomic force microscopy (AFM) were 
employed to determine the shape and surface morphology of the nanoparticles. 
Before SEM observation, the particles were fixed on a tip and coated with platinum 
by an Auto Fine Coater (JFC-1300, JEOL USA). AFM was conducted with 
Nanoscope IIIa in the tapping mode. The nanoparticle sample was mounted on a 
metal slabs using double-sided adhesive tapes and scanned by the AFM maintained in 
a constant-temperature and vibration-free environment.  
3.2.1.3 Encapsulation efficiency of paclitaxel 
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This experiment was performed in triplicates using high performance liquid 
chromatography (HPLC) to determine the concentration of paclitaxel extracted from 
the nanoparticles. Briefly, 3 mg of nanoparticles was dissolved in 1 ml of DCM to 
extract paclitaxel from the nanoparticles. DCM was allowed to evaporate overnight. 3 
ml of acetonitrile/ water (50:50, v/v) was added and the solution was votexed for 1 
min. After which, the sample was filtered through a filter membrane (0.45 um pore 
size) and transferred to HPLC vials. The mobile phase of HPLC was composed of 
acetonitrile and water of 50/50 (v/v). 
3.2.1.4 In vitro release of paclitaxel 
The release of paclitaxel from the nanoparticles was measured using HPLC. Five 
batches of particles that were made were used for the study. The study was carried out 
in triplicates. 5 mg of the paclitaxel-loaded nanoparticles were weighed into 
individual centrifuge tubes and suspended in 10 ml of fresh PBS. The tubes were 
placed in a 37oC orbital shaker water bath and shaken horizontally at 120 min-1.  
The tubes were taken out at particular time intervals and centrifuged at 13000, 18oC, 
15 minutes. The supernatant was removed and taken for in vitro release analysis. 
The predipitaed nanoparticles were re-suspended in 10 ml PBS, sonicated, vortexed 
and placed back into the water bath shaker. Paxlitaxel in the supernatant was 
extracted in 1 ml of DCM in a separation funned. The funned was shaken consistently 
and 2 layers would form. The top layer contained water while the bottom layer 
contained DCM and the extracted paclitaxel. DCM was collected and allowed to 
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evaporate overnight. 3 ml of acetonitrile/ water was added after evaporation and 1ml 
of the solution was transferred to the HPLC vials. The condition of the HPLC 
analysis was the same as described in the determination of encapsulation efficiency. 
3.2.1.5 Cell culture and cellular uptake experiments 
Cell culture 
MDCK cells were cultured in 25 ml flasks in a humidified 5% CO2/95% air incubator 
at 37°C. The culture medium was DMEM supplemented with 10% FBS, 100 ug/ml 
penicillin G and 100 ug/ml streptomycin sulfate. After growing to confluent, the cells 
were washed with 5 ml PBS and rinsed with 2 ml trypsin twice. Then, 3 ml trypsin 
was added to the cells and the flask was kept in the incubator at 37°C for about 15 
minutes. Five ml medium were added to the flask and the cell suspension were 
transferred to a 15 ml centrifuge tube. The cells were collected by centrifugation for 5 
minutes at 1000 rpm.  
Cellular uptake experiments 
For quantitative uptake experiments, MDCK cells were seeded in 96 well plates. 
After the cells reached confluent, the medium was removed and replaced with 100 ul 
of Hank’s balance salt solution (HBSS). Cells were incubated for 1 h in HBSS for 
balance. Fluorescence labeled nanoparticles suspensions of different concentrations 
were then added to the cells and the plate was incubated for 4 hours. Uptake was 
terminated by washing the cells for three times using PBS. The cells were solubilized 
by triton/0.2N NaOH. The plate was then scanned with a micro plate reader 
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(excitation wavelength 430 nm, emission wavelength 485 nm) to measure the amount 
of fluorescence in each well. 
For confocal laser scanning microscopy imaging, MDCK cells were seeded at a low 
density in 4-chamber coverless system and were observed next day after seeding. The 
medium was removed and replaced with 500 ul of HBSS. Cells were incubated for 1 
h in HBSS and fluorescence labeled nanoparticles suspensions were added to the cells. 
After 1 hour incubation, nanoparticles suspensions were removed and the cells were 
washed with PBS for three times. The cells were then fixed with formaldehyde and 
the cell membrane was counterstained with fm4-64 for 1 hour at the room 
temperature. Then the cells were observed under confocal laser scanning microscopy.  
3.2.2 Gd-DTPA Loaded Nanoparticles of Biodegradable Polymers for MRI of 
the Brain 
3.2.2.1 Fabrication of nanoparticles  
To prepare Gd-DTPA loaded nanoparticles, three polymers were used, including 
PLGA, PLA-PEG (90:10), and PLA-PEG (70:30). PLA-PEG copolymers were 
synthesized by Mr Dong Yuancai in the Chemotherapeutic Engineering laboratory of 
NUS. The nanoprecipitation method was used to prepare Gd-loaded nanoparticles. 
Briefly, 75mg polymer was dissolved in certain amount of acetone, and 0.3ml Gd-
DTPA solution was suspended in the polymer solution by sonicated by 20 seconds. 
The resultant suspension was added drop by drop to 25ml water with 100 mg F-68. 
The organic solvent was then evaporated under vacuum. Finally, the particles were 
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collected by centrifugation at 12,000 rpm for 80 minutes and freeze dried to obtain 
fine powder.  
3.2.2.2 Encapsulation efficiency of Gd-DTPA 
The encapsulation efficiency and drug content of the particles were studied by 
inductively coupled plasma-atomic emission spectrometry (ICP-AES). Briefly, 
certain amount of particles was dissolved by 1 ml DCM and votexed for 3 minutes. 
After that, DCM was evaporated. Gd-DPTA was extracted by water. Then the 
samples were filtered by 0.22um syringe driven filters and the concentration of Gd in 
the solution was determined by ICP-AES.  
3.2.2.3 In vitro release of gadolinium 
The in vitro release profile of gadolinium from the particles was studied in PBS at 
37°C and the method was based on a dynamic dialysis. The study was carried out in 
triplicates. Briefly, the Gd-DTPA loaded nanoparticles were dispersed using 5 ml 
PBS inside dialytic tubing and were incubated in 35 ml of extra-dialytic tubing PBS 
with shaking. Sampling was carried out at predetermined time intervals from extra-
dialytic tubing test medium. The same amount of PBS was added to the extra-dialytic 
medium. Released gadolinium in the sample was measured by ICP-AES. 
3.2.2.4 In vitro and in vivo MRI 
Before the Gd-DTPA loaded nanoparticles were used on animals, in vitro test in tube 
was carried out. Briefly, the particles were suspended in water and scanned by MRI 
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first. Then, the suspension was filtered by a 220 nm syringe driven filter. The 
filtration was scanned by the MRI. The values indicating the density of gadolinium 
before and after filtering were compared to find out the amount of released and 
remaining gadolinium in the particles.  
For in vivo MRI experiment, healthy rats about 200-220 g were used. Each rat was 
intravenously injected at a dose of 1 ml in tail vein, respectively. Those injections 
were suspensions containing the preparations of nanoparticles. The animals were 

















RESULTS AND DISCUSSION 
4.1 IN VITRO EVALUATION OF PLGA NANOPARTICLES FOR 
PACLITAXEL DELIVERY ACROSS THE BLOOD BRAIN 
BARRIER  
4.1.1 Particle Size and Size Distribution 
Totally five batches of PLGA nanoparticles were prepared by the method of single 
emulsion solvent evaporation. Sample 1 was PLGA nanoparticles emulsified with 
PVA. Sample 2, 3 and 4 were the PVA emulsified PLGA nanoparticles coated with 
Tween 80, poloxamer 188 and poloxamer 407, respectively. Sample 5 was VE-TPGS 
emulsified PLGA nanoparticles. The size averaged by particle volume and 
polydispersity of all samples were determined by laser light scattering. Table 4 shows 
the particle size and size distribution of the particles. The results are mean value of 6 
measures. 
Particle size plays important roles in determining the intracellular uptake of 
nanoparticles and determining the fate of the nanoparticles after administration. It is 
also one of the key factors in determining whether the particle can cross the blood 
brain barrier. It was reported that smaller particles tended to accumulate in the tumor 
site due to the facilitated extravasation [131] and a greater internalization was also 
observed [132]. Particles less than 200 nm can prevent spleen filtering [133]. In 
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addition, smaller particles make intravenous injection easier and their sterilization 
may be simply done by filtration [134, 135]. 
In our study, as shown in table 4 below, the size of all the particles was within 250 to 
280 nm. A variety of particles ranged in size from less than 100 nm to more than 300 
nm had been investigated to cross the blood brain barrier [136-139]. Generally 
particles in size from 250 to 280 were possible to cross the blood brain barrier. For 
Sample 1, the PVA emulsified nanoparticles, had a size of 257.1 nm. When the 
particles were coated with tween 80, poloxamer 188 and poloxamer 407, the sizes 
were increased by 1.5, 27.0, and 11.1 nm, respectively. The increase of the sizes 
could be attributed to the formation of an adsorbed coating layer on the particle 
surface. All the three coating materials are amphiphilic molecules and they may be 
adsorbed to the particle surfaces from an aqueous solution through hydrophobic 
interaction of the hydrophobic moiety with the particle surface. The hydrophilic 
blocks extend into the aqueous medium to form a hydrophilic layer.  The thickness of 
the layer may be determined by the length of the hydrophilic part of the molecule and 
the conformation of the hydrophilic part. This may explain the different on size 
increase of the coated particles. For sample 5, the particles emulsified with VE-TPGS, 
the size was 14 nm larger than that of sample 1. It may due to the structure of the 
emulsifiers. As shown in figure below, the structure of PVA is a long linear chain. 
The molecular weight is 30000-70000. VE-TPGS is a water-soluble derivative of 
natural vitamin E, which is formed by esterification of vitamin E succinate with 
polyethylene glycol 1000. The molecular weight of VE-TPGS is only 1,513, which is 
much lower than that of PVA. In the formation of the nanoparticles, the emulsifier 
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was on the interface of oil droplet and the water phase, and helped to stabilize the 
nanoemulsion droplet. The long chain of PVA made it more effective in stabilizing 
the droplet which leaded to smaller particle. However, considering the amount of 
PVA (0.6g) and VE-TPGS (36mg) used, the emulsifying efficiency of TPGS was 
much bigger than that of PVA. This could be due to the unique physicochemical 
properties of Vitamin E TPGS. VE-TPGS is a miscible with water and forms solution 
with water at concentration up to ~20% (w/w), beyond which liquid crystalline 
phases may form. The amphiphilic characteristic of the TPGS molecule leads to its 
self-association in water when concentration exceeds a threshold known as the critical 
micelle concentration (CMC), which is ~0.02 wt% in water. Above CMC, TPGS 
begins to forms micelles and continues to form relatively low viscosity solutions with 
water until a concentration of ~20 wt% is obtained. When the TPGS concentration is 
above this value, higher viscosity liquid crystalline phases start to form. In fabrication 
of nanoparticles by the single emulsion solvent evaporation technique, the role of the 
surfactant stabilizer is to stabilize the dispersed-phase droplets and inhibit 
coalescence. The amphiphilic surfactants align themselves at the droplet surface so as 
to promote stability by lowering the free energy at the interface between two phases 
and resisting coalescence and flocculation of the nanoparticles. However, at higher 
concentration, the state of TPGS in the aqueous dispersing phase has changed and it 
can not exert a stabilizing effect on the formation of emulsion system, droplet 
separation and stabilization, as well as nanoparticles hardening. In contrast, it was 
evident that when the concentration was too low, it did not act as an emulsifier. 
Therefore, TPGS would not be able to perform as a good surfactant at both higher and 
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lower concentrations and could not produce nanoparticles with ideal properties. This 
may explained that TPGS at low concentration was a good emulsifier for PLGA 
nanoparticle fabrication. This characteristic of VE-TPGS makes it a good emulsifier 
because the low amount used in nanoparticle preparation leads to easy washing of the 
remaining emulsify on the surface of the particles. Moreover, VE-TPGS may have the 
potential to improve nanoparticle adhesion to cells and the hemodynamic properties 
of the nanoparticles in the blood flow while remaining PVA has negative effects on 
cellular uptake of the particles. This provides advantages of VE-TPGS emulsified 
nanoparticles to the PVA emulsified particles. From table 4 it can also be seen that 
the polydispersity of the particles was from 0.009 to 0.17. The relatively low 
polydispersity indicated that the particles prepared by single emulsion solvent 
evaporation method had a narrow distribution of the particle size.  
                 
Fig 7   Chemical structure of PVA and VE-TPGS 
Sample Matrix/Emulsifier/Coating Particle Size (nm) Polydispersity 
1 PLGA /PVA/-- 257.1 0.113 
2 PLGA /PVA/Tween 80 257.6 0.126 
3 PLGA /PVA/Poloxamer 188 284.1 0.009 
4 PLGA /PVA/Poloxamer 407 268.0 0.101 
5 PLGA /TPGS/-- 274.1 0.17 
Table 4: Size and Size Distribution of different nanoparticles 
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4.1.2 Zeta Potential 
Zeta-potential indicates the surface charge of the nanoparticle. The surface charge can 
greatly influence the particles stability in suspension through the electrostatic 
repulsion between the particles. It is also an important factor to determine their 
interaction in vivo with the cell membrane, which is usually negatively charged. In 
addition, from the surface charge the dominated component on the particle surface 
can be roughly known.  
The zeta potential of the five samples was measured by the laser Doppler 
anemometry. The results are shown in table below. The results were mean value of 6 
measures. From the results it can be seen that the zeta potential of all the five samples 
was negative. The zeta potential of sample 1, the PVA emulsified nanoparticle was -
13.72 mV. When the particles were coated with Tween80, poloxamer 188 and 
poloxamer 407, the particles tended to be more negatively charged. For sample 5, the 
particles emulsified with VE-TPGS, they were even more negatively charged than all 
the PVA emulsified particles.  
Generally, the surface charge of the nanoparticles was determined by the materials 
presented on the surface of the nanoparticles. In our study, the particles were prepared 
using PLGA, PVA or TPGS and the surface coating materials. It has been reported 
that the zeta potential of PLGA nanoparticles without any PVA in neutral buffer is 
about -45 mV [140]. This high negative charge is attributed to the presence of 
uncapped end carboxyl groups of the polymer at the particle surface. But the zeta 
potential of our nanoparticles could not be -45 mV because there were remaining 
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emulsifiers or coating materials on the surface of the particles. In several studies, a 
clear differentiation in the zeta potential values of coated and non-coated 
nanoparticles was reported, with generally highly negative zeta potential values for 
non-coated nanoparticle and less negative zeta potential values for coated 
nanoparticles. Coating of nanoparticles with some amphiphilic polymers normally 
decreases the zeta-potential because the coating layers shield the surface charge and 
move the shear plane outwards from the particle surface [141, 142]. Redhead et al. 
have reported a similar reduction in the zeta potential of PLGA nanoparticles after 
coating with amphiphilic polymers like poloxamer 407 and poloxamine 908 [143]. In 
our study, the first four samples were emulsified by PVA. PVA on the particle surface 
could not be moved completely even after repeated washings because it forms an 
interconnected network with the PLGA at the interface. The remaining PVA may 
shield the surface charge of PLGA. This may explain why the zeta potential of 
sample 1 was -13.72 mV. Sample 2, 3, 4 were coated with Tween 80, poloxamer 188 
and poloxamer 407, respectively. The zeta-potential results reflected the presence of 
the adsorbed layer on the particle surface. A reduction of the absolute value of the 
zeta potential indicated that the particles were successfully coated with these 
materials in the solution. For sample 5, the VE-TPGS emulsified nanoparticles, it had 
a zeta potential which was more negative than all the other samples. Compared with 
sample 1, the PVA emulsified nanoparticles, the differentiation was especially 
obvious. This may attributed to the difference of these two emulsifiers. As discussed 
in the previous part, the properties of the two emulsifiers are distinct, which lead to 
different amount needed in the particle preparation. In the present study, 0.6 g PVA 
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and 36mg VE-TPGS were used in nanoparticle preparation, respectively. Moreover, 
the molecular weight of VE-TPGS was much lower than that of PVA. Thus, the 
remaining VE-TPGS in the particles was much easier to be washed away. It could be 
concluded that less remaining of the emulsifier lead to less shield of PLGA charge. 




1 PLGA /PVA/-- -13.72 
2 PLGA /PVA/Tween 80 -23.13 
3 PLGA /PVA/Poloxamer 188 -17.45 
4 PLGA /PVA/Poloxamer 407 -21.87 
5 PLGA /TPGS/-- -28.5 
 
4.1.3 Drug Loading and Drug Encapsulation Efficiency (EE) of Paclitaxel 
The encapsulation efficiency represents the proportion of the initial amount of drug 
which has been incorporated into the particles. It is an important index for the 
evaluation of the device, especially for the expensive drugs such as paclitaxel. There 
are several factors that may affect the encapsulation efficiency of the drug, such as 
the hydrophobocity of the drug, the size of the particles, and the emulsifier.   
High performance liquid chromatography (HPLC) was used to determine the amount 
of paclitaxel extracted from the nanoparticles. Encapsulation efficiency of the 
nanoparticles was calculated by equation 1. From the equation it can be seen that to 
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calculate the original materials used in preparation, only the mass of polymer and 
drug used in formulation were counted. The mass of the coating materials could not 
be known clearly because they were absorbed on the particles from the aqueous 
solution. Thus, only EE of naked particles, sample 1 and sample five were calculated.  
The results were shown in figure 8 below. Encapsulation efficiency of sample 1, the 
PVA emulsified nanoparticles, was 46.93%, while that of sample 5, the VE-TPGS, 
emulsified nanoparticle was 91.14% 
Encapsulation efficiency (%) =
nformulatioin  used drug andpolymer  of Mass
nformulatioin  used drug of Mass
100
lenanopartic of Mass
lenanoparticin  drug of Mass ×
     (1) 
In our study, paclitaxel was used as a model drug. It was a highly hydrophobic drug 
which can be seen from its chemical structure in figure 9. It tends to remain in the oil 
phase in the process of fabrication. This may explain that the encapsulation efficiency 



















Fig. 8  Encapsulation efficiency of the nanoparticles. Sample 1 is PVA emulsified 
nanoparticles. Sample 5 is TPGS emulsified nanoparticles. 
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 Fig. 9  Chemical structure of paclitaxel 
Though the encapsulation efficiency of both sample 1 and sample 5 was relatively 
high, the values were significantly different. The EE of sample 5 was almost two 
times of that of sample 1. Considering the size factor, the size of the particles were 
similar, it could be affect the encapsulation of the paclitaxel significantly. Another 
factor should be the emulsifier. The advantage of VE-TPGS in increasing the 
encapsulation efficiency of the particles could be seen. It can also be seen that the EE 
of the VE-TPGS emulsified nanoparticles was almost two times of that of the PVA 
emulsified nanoparticles, while the amount of VE-TPGS used was much lower than 
that of PVA. It has been reported that the EE could even reach 100% when the drug 
loading ratio was increased to 10% [144]. This achievement significantly improves 
the solvent evaporation/extraction technique for fabrication of nanoparticles. It is 
normally difficult to approach such high encapsulation efficiency. The droplet 
formation, droplet stabilization, nanoparticle hardening is the three essential stages of 
nanoparticle formation. The formation of solid nanoparticle is brought about by the 
diffusion of solvent from the emulsion droplet into the continuous phase, followed by 
the evaporation/extraction of the volatile solvent and the simultaneous inward 
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diffusion of the non solvent into the droplet. During this course, a partition occurs 
across the interface from the dispersed phase to the continuous phase. However, the 
partition is not limited to the organic solvent; both the polymer and the drug 
molecules may also partition or diffuse across this interface from the organic phase 
toward the external aqueous phase. The partitioning phenomenon between the 
dispersed and the dispersing phases contributes to a substantial lowering of 
microencapsulation yield as well as the encapsulation efficiency. Although the 
physicochemical characteristic of the drug molecule plays an important role, the 
surfactant character also has significant effect on the localization of the drug molecule. 
Modifying the dispersed or dispersing phase of the emulsion by the emulsifier/ 
stabilizer to reduce the leakage of the drug molecule from the oily droplets can thus 
make improvement of the encapsulation efficiency of the drug in the nanoparticles. In 
our study, the bulky and large surface area of TPGS resulting from its big lipophilic 
alkyl tail (polyethylene glycol) and hydrophilic polar head portion (tocopherol 
succinate) could effectively protect the diffusion or partition of the hydrophobic 
paclitaxel from polymer to external phase. The encapsulation efficiency of paclitaxel 
in the polymeric nanoparticle can thus be significantly improved.  
As mentioned previously, for those nanoparticles which had been coated by other 
materials, the EE can not be calculated accurately because the amount of the coating 
materials in the nanoparticles had not been determined. Thus, drug content was also 
calculated by equation 2.  
Drug Content (% w/w) = 
lenanopartic of Mass
100lenanoparticin  drug of Mass ×
                                    (2)                                     
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From fig. 10 it can be seen that the drug content ranged from 1.20% to 4.44%. For 
sample 1 to sample 4, the drug content of particles with coating were lower than that 
of the particle without coating, this should be resulted from addition of the coating 
materials on the mass of the particles. Imagine that same amount of naked 
nanoparticles was prepared, with addition of the coating materials, the mass of the 
nanoparticle will be increased, and thus the drug content will be decreased. The 
extent drug content decreased may relatively indicate the amount of coating materials 


























Fig 10 Drug content of the nanoparticles  
4.1.4 Morphology  
The morphology of the nanoparticles was studied by scanning electrical microscopy 
(SEM) and atomic force microscopy (AFM). The results were shown in the figures 
below.  
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From the SEM picture it can be seen that the nanoparticles had fine spherical shape 
and smooth surface. The coating seems to have little effect on the morphology of the 
nanoparticles. There was no aggregation between the particles.  AFM technique has 
been widely applied to provide surface-dependent information in three dimensions on 
a nanometer scale. It is capable of resolving surface details down to the atomic level 
and can give morphological images in high resolution. It is not possible to get optimal 
image for solid nanoparticles in general. The images of the shape and surface 
characteristic of the nanoparticles were obtained successfully by applying tapping 
mode AFM. The AFM images reveal the fine structure of the nanoparticles surface. 
They gave clear 3-D images of spherical nanoparticles and confirmed that there was 
no aggregation or adhesion among the nanoparticles.  
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Fig 11 SEM and AFM images of the nanoparticles (from top to bottom: Sample 
1,PVA emulsified nanoparticles; sample 2, PVA emulsified Tween 80 coated 
nanoparticles; sample 3, PVA emulsified poloxamer 188 coated nanoparticles; 
sample 4, PVA emulsified poloxamer 407 nanoparticles; sample 5, TPGS emulsified 
nanoparticles). 
4.1.5 In Vitro Release of Paclitaxel 
In vitro release profile of the drug from the nanoparticles is a very important property 
of the drug delivery system. One of the main advantages of using nanoparticles to 
cross the blood brain barrier is that nanoparticles may provide sustained release of 
drug in the brain to prolong the pharmacological action of drug molecules. The in 
vitro release experiments may predict behavior of the drug after the nanoparticles is 
administered to the patients, which included the amount the released drug and time 
the release may last. 
The in vitro release profile of paclitaxel from the nanoparticles was studied by HPLC. 
The figure below shows the drug release profile in one month when the particles were 
incubated in PBS at 37oC with shaking. As shown in the figure, sample 1, 2, 3 and 4 
are nanoparticles emulsified with PVA. These particles may have similar profile in 
drug release. They had an initial release burst during the first five days of the release, 
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which was around 50%. The release gradually decreased and was constant even after 
one month. At the end of one month, about 60% to 80% drug was released. Their 
trends were similar. For sample 5, the VE-TPGS emulsified nanoparticle, the rate of 
drug release was much slower than the PVA emulsified nanoparticles. Also, the initial 
burst was not as big as that of the PVA emulsified particles. 
The diffusion of the drug, the erosion and swelling of polymer matrix and the 
degradation of polymer are the main mechanisms for the drug release. Since the 
degradation of PLGA is slow, the release of paclitaxel from the nanoparticles would 
mainly depend on the drug diffusion and the matrix erosion. In such case, the size, 
hardness and porosity of the nanoparticles should have significant effects on the 
release property. The AFM and SEM observation indicated that all the nanoparticles 
had smooth surface, which supported the slow release of drug by diffusion and matrix 
erosion mechanism. Moreover, the reason of TPGS emulsified nanoparticles 
displayed slow release may come from the enhanced interaction or affinity between 
paclitaxel and polymer matrix. Not only does VE-TPGS possess amphiphilic property, 
which is necessary for surface-active agents, but it can be dissolved in both the oil 
and the water phase as well. The TPGS can always be well distributed in water phase 
or in the oil phase. In addition, the TPGS molecules are bulky and have a large 
surface area. When forming the emulsion system, TPGS could have the drug and the 
polymer in a better contact and thus every droplet can be blended thoroughly inside 
the oil phase. However, PVA does not possess such a property and can thus not be 
distributed in the oil phase. Nevertheless, further investigations are needed to make a 



































Fig 12 The release profile of paclitaxel from the nanoparticles in PBS 
Furthermore, the in vitro release profile demonstrated in PBS buffer could not 
accurately reveal the real behavior of the drug after the nanoparticles were 
administered to the patients. In human blood, there are many proteins and molecules 
which may interact with the nanoparticles and change the profile of drug release. It is 
necessary to further investigate the release profile of drug from the nanoparticles in 
serum. 
 4.1.6 Cell Culture 
In vitro evaluation of nanoparticles across the blood brain barrier was carried out 
using MDCK cells. The blood-brain barrier (BBB) is the tightest barrier known in 
physiology, for its ability to select and control transported substances. The physical 
barrier is provided by the endothelial cells, but data has suggested that factors 
secreted by adjacent cells (astrocytes and pericytes) play a major role in the 
modulation of cell-cell junctions. MDCK has been used as in vitro models for the 
BBB as it is endowed with the ability to form polarized monolayers that express tight 
junctions in the apical side. MDCK cells also produce many of the enzymes found in 
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the brain endothelial cells. Under appropriate culture condition, monolayers with 
tightness comparable to that found in the brain endothelial cells, can be obtained 
within days of culture. MDCK monolayers represent a relatively simple model for the 
screening of compounds that are transported passively across the blood-brain barrier. 
Primary brain endothelial cells can also be utilized as a blood-brain barrier screening 
model for predicting brain permeability. However, the effort required in isolating and 
characterizing primary brain endothelial cells, along with the batch-to-batch 
variability of these freshly isolated cells, render this model unattractive for routine 
use. More consistent results are obtained with cell lines that can be maintained in 
continuous culture. Since brain endothelial cell lines are not available, alternatives 
have been developed using other endothelial cells. MDCK cell line is one of them. 
Figure 13 shows the morphology of MDCK cells at low (left) and high (high) density. 
Compared with the bovine brain microvascular endothelial cells (BBMVEC) in figure 
14, they had similar morphology.  
       
Fig 13 Morphology of MDCK cells at low density (left) and high density (right). 
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 Fig 14 Morphology of bovine brain microvascular endothelial cells (BBMVEC) 
 
4.1.7 Cellular Uptake of Nanoparticles 
In order to study cellular uptake of nanoparticles in vitro in vivo, the use of 
fluorescently or radioactively labeled nanoparticles is the most common experimental 
approach found in the literature. Fluorescent labeling was chosen for the present 
study to avoid exposure of the samples to the radioactive materials. Fluorescent 
labeling makes cellular uptake of nanoparticles readily detectable by fluorescence 
microscopy or CLSM. The extent of particle uptake can then be determined by flow 
cytometry, fluorometry, or quantitative extraction of the markers from the cells.  
As fluorescent markers are sensitive to the environment, their use in nanoparticle 
visualization can lead to misinterpretation of nanoparticle uptake data due to the 
leaching or dissociation of fluorescent markers into the released medium and hence 
subsequently into the cells. Neither could fluorometric analysis differentiate between 
intracellular and surface located particles, nor determine whether fluorescence 
detected was due to the cell-associated particles or the fluorescence released from the 
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particles in the medium which was subsequently taken up by the cells. However, the 
association of the marker cormarin-6 with the nanoparticles has been demonstrated by 
in vitro release experiment.  It has been shown that only a small part of the markers 
was released from the particles and the result was believable [145].  
In our study, the nanoparticles were washed, freeze-dried and kept in vacuum 
desiccator after preparation or coating process. The repeated washing process was to 
ensure that the surface materials adsorbed on nanoparticles were not able to deviate 
from the particle surface in cell uptake experiments. To carry out cell uptake 
experiments, the dried fluorescence labeled nanoparticle were dispersed in PBS 
buffer and incubated with MDCK cells and the particle internalized in the cells were 
measured by a microplate reader.  
As shown in fig. 15 below, 33.5% of sample 1, the PVA emulsified particles, could 
be internalized in MDCK cells. When coated with Tween 80, poloxamer 188 or 
poloxamer 407, the uptake could be increased to 53.0%, 51.7 and 61.3%, respectively. 
For sample 5, the VE-TPGS emulsified nanoparticle, 61.3% particles was internalized, 
which was almost twice of the naked PVA emulsified particles. 
Intracellular uptake of nano- and microparticles has previously been shown to depend 
on the size and the hydrophobicity of the carrier [132, 146]. In general, the uptake 
decreases with increasing size and with increasing hydrophilicity. In our study, firstly, 
it can be seen that PLGA particles below 300 nm was possible to cross the blood 
brain barrier. This may due to the small size of the particles. Intracellular particulate 
uptake could either be by phagocytosis or by fluid phase endocytosis [147]. A number 
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of previous reports have demonstrated phagocytic uptake of nano- and microparticles 
in macrophages with a lower cut-off size for such a phagocytic uptake being about 
0.5um [148]. For nanoparticles of lower size, the main route of intracellular entry is 
through fluid phase endocytosis. In our study, the size of all the particles was below 
300 nm. It may be suggested that the route of uptake may be fluid phase endocytosis. 
Secondly, it can also be seen that the differences in the surface properties of the 
formulations have contributed to the difference in uptake.  One reason may be the 
effects of residual PVA on the surface of particles. After coated with other materials, 
the PVA emulsified nanoparticles increased a lot in intracellular uptake in MDCK 
cells. This could be attributed shielding of PVA by these materials. It has been 
reported that relatively high concentration of residual PVA may decrease the 
intracellular uptake of nanoparticles [149]. Another reason may be the surface 
hydrophobicities. For the five samples, the surfaces were coated with PVA, Tween 80, 
































Fig. 15  Cellular uptake of nanoparticles in MDCK cells  
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To visualize the nanoparticles in the MDCK cells, confocal laser scanning 
microscopy was employed to take the images of fluorescence labeled nanoparticles 
incubated with MDCK cells. Figure 16 shows the images of particles internalized in 
MDCK cells. It can be seen that the particles (in green) were internalized the cyto 

















Fig. 16 Confocal laser scanning microscope images of PLGA nanoparticles 
internalized in MDCK cells ( Sample 1,PVA emulsified nanoparticles; sample 2, PVA 
emulsified Tween 80 coated nanoparticles; sample 3, PVA emulsified poloxamer 188 
coated nanoparticles; sample 4, PVA emulsified poloxamer 407 nanoparticles; 
sample 5, TPGS emulsified nanoparticles) 
 
4.2 GD-DTPA LOADED NANOPARTICLES OF 
BIODEGRADABLE POLYMERS FOR MRI OF THE BRAIN 
4.2.1 Particle Size 
PLGA and PLA-PEG were used to prepare nanoparticles by nanoprecipitaiton 
method. Totally four batches of samples were prepared. Sample 1 was prepared using 
PLGA. Sample 2 and 3 was prepared using PLA-PEG (90:10) with different 
concentration of the polymer. Sample 4 was prepared using PLA-PEG (70:30). 
Particle size was determined by laser light scattering. The results are mean value of 6 
measures. 
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Size and size distribution play important roles determining the fate of the 
nanoparticles after administration. Especially for crossing the blood brain barrier, 
smaller size is preferred. As discussed previously, particles smaller than 100 nm are 
ideal for crossing the blood brain barrier. However, particle size also affects the 
encapsulation efficiency of the drug. Usually, the size is smaller, the EE is lower. 
This is because that the small particles have a high surface area compared to their 
volume and a high proportion of the drug which is incorporated will be at or near the 
surface of the nanoparticles and can be readily released during nanoparticle 
production or during the removal of unincorporated drug.  
Table 6 shows the results of size and size distribution of the particles. From the 
results of particle size it can be found the size of these particles were very small. 
Except sample 1, the PLGA nanoparticles, all the other samples were less than 100 
nm, which were very suitable for crossing the blood brain barrier. This could be 
attributed to the structure of the polymer. It can be seen that the proportion of PEG in 
the polymer played an important role in determining the size of the particle. The 
larger the PEG proportion, the smaller the size was. This may due to the 
hydrophobicity of the polymer. In the process of particle fabrication by 
nanoprecipitation, the nanoparticles were formed by the interfacial turbulence 
resulted from the rapid diffusion of water miscible solvent to the water. The energy 
released in this diffusion process provides the formation of the particles [150-152]. 
The faster the diffusion is, the smaller the particle size would be. For this kind of 
polymer, the part of PLA is hydrophobic and the part of PEG is hydrophilic. With 
more PEG part, the diffusion rate of the polymer solution into the water should be 
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faster. This may explain why the particle size of sample 4, PLA-PEG (70:30) particle, 
was much smaller than that of sample 3 PLA-PEG (90:10) particle while other 
conditions were similar.  
 Furthermore, the concentration of the polymer solution also affected the size of the 
particles. The size of sample 2, with the polymer concentration of 0.94% (w/v), was 
16.1 nm smaller than that of sample 3, with the polymer concentration of 1.5%. This 
was due to the same reason, the diffusion rate of the polymer solution in the water 
phase. When the concentration of the solution was increased, the viscosity of the 
solution was also increased, which made the diffusion rate of the polymer into the 
water slower.  
Table 6: The size and polydispersity of the Gd-DTPA loaded particles 
Sample Polymer : Solvent Size Polydispersity 
1 PLGA (75mg) : Acetone (8ml) 284.8±5.9 0.136±0.034 
2 PLA-PEG (90:10) (75mg) : Acetone (8ml) 83.2±0.7 0.169±0.025 
3 PLA-PEG (90:10) (75mg) : Acetone (5ml) 99.3±1.1 0.215±0.011 
4 PLA-PEG (70:30) (75mg) : Acetone (5ml) 81.0±5.5 0.236±0.028 
4.2.2 Morphology  
The morphology of the Gd-loaded particles was investigated by SEM. The image of 
PLGA nanoparticles was shown in fig 17; the image of PLA-PEG nanoparticles was 
shown in fig. 18.  
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 Fig 17 SEM image of PLGA nanoparticle 
 
Fig 18 SEM image of PLA-PEG nanoparticles 
From the picture it can be found that the morphology of PLGA nanoparticles was 
different from that of the particles made by single emulsion solvent evaporation 
methods although their size was similar. It can be seen that there were aggregations 
among the particles. This may be due to the difference of the manufacturing process. 
In the nanoprecipitation method, only 100 mg F-68 was used dissolved in the water 
68 
phase and it could be more easily washed away than PVA or VE-TPGS in the 
centrifugation step.  Thus, after freeze dry, the particles may be aggregated because 
there was less remaining surfactant or coated materials on the particle surface.  
Compared the PLGA and PLA-PEG nanoparticles, there were differences between 
the two samples. Firstly, as reflected in the result of the laser light scattering study, 
their size was different. The PLGA particles were much larger than the PLA-PEG 
particles. Secondly, there was no significant aggregation in PLA-PEG particles 
compared with the PLGA nanoparticles. 
It can also be seen from the picture that the size of PLA-PEG nanoparticles was less 
than 50 nm. This may attribute to the process of freeze drying. The lose of water from 
the particles made them smaller than measured in suspension by laser light scattering.  
4.2.3 Loading and Encapsulation Efficiency of Gadolinium 
The amount of Gd-DTPA extracted from the nanoparticles was determined by ICP-
AES. The results are shown in the table below. The results are mean value of three 
measures. 
Encapsulation efficiency and drug content are important factors to be considered. A 
nanoparticle system with high encapsulation efficiency and drug content will reduce 
the quantity of carrier required for the administration of sufficient amount of active 
compound to the target site as well as drug wastage during manufacturing. However, 
for all the water soluble drugs, a big problem is the poor encapsulation efficiency and 
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drug content. The low encapsulation efficiency and drug content are mainly due to 
rapid migration of the drugs from the particles to the external aqueous phase.  
In our study, Gd-DTPA was used to label the nanoparticles and facilitate the 
visualization of particles by the MRI. In the MRI imaging experiment, the amount of 
gadolinium needed in one experiment is fixed. Therefore, high encapsulation 
efficiency and drug content were very important because they would lead to less 
usage of nanoparticles in one injection. This will also make the injection quicker and 
easier.  
As the results shown in table 7, the encapsulation efficiency of gadolinium was very 
low. Sample 2 and 3 had EE of 1.79% and 3.63%. This means that almost all of the 
Gadolinium leaked from the particles into the water. EE of sample 4 was 12%. Even 
for this sample, most of the Gadolinium migrated from the particles into the water 
phase. From the results it can be seen that the hydrophilic nature of Gd-DTPA 
resulted in a significant loss of the drug to the external aqueous phase during the 
production process.  Compared sample 3 and 4, it can be seen that the structure of the 
polymer also affected the EE of the nanoparticles. The EE of sample 4 was about 3.3 
times of that of sample 3. This may due to the hydrophilicity of polymer. Sample 4 
was made up of PLA-PEG (70:30) while sample 3 is made up of PLA-PEG (90:10). 
The PEG part in the polymer was hydrophilic. The drug was also hydrophilic. There 
may be more interactions between the polymer and the drug, which leaded to a higher 
encapsulation efficiency. Furthermore, the effects of particle size on the encapsulation 
efficiency could also be seen from the results. From the results of size, the sequence 
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of size from large to small was sample 3, sample 2, and sample 4. In the results of 
encapsulation efficiency, the sequence was reversed. This was because that the small 
particles have a high surface area compared to their volume so that a high proportion 
of the drug which is incorporated will be at or near the surface of the nanoparticles 
and this part of the drug can be readily released during nanoparticle production.  
For sample 1, the PLGA nanoparticle, the content of drug in the particle was not 
uniform among the triplicate samples and can not be determined accurately. 






Sample Polymer : Solvent 
Gd Gd-DTPA Gd 
Gd-
DTPA 
2 PLA-PEG (90:10): Acetone (8ml) 1.79 2.45 0.26 0.92 
3 PLA-PEG (90:10): Acetone (5ml) 3.63 4.96 0.53 1.86 
4 PLA-PEG (70: 30) : Acetone (5ml) 12.00 16.37 1.76 6.14 
 
4.2.4 In Vitro Release of Gadolinium 
In vitro release of Gd-DTPA is an important profile that must be demonstrated before 
the animal study. It can give out a rough prediction on the fate of gadolinium after the 
nanoparticles were injected in the animals. Gd-DTPA will be imaged by the MRI 
whether it is incorporated in the nanoparticle or released from the particles. Thus, it is 
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necessary to get the prediction of the release profile from the particles so that the 
image can be analyzed objectively.  
Figure 19 shows the release profile of gadolinium from the particles. Sample 3 and 
sample 4 were chosen for this characterization because they had relatively high 
encapsulation efficiency and may be used for further experiments. From the results it 
can be seen that for both samples small part of the drug was released in 24 hours. The 
rate of release was slow. For sample 3, about 15% of the gadolinium was released in 
3 hours and after that about 20% of the gadolinium was released in 21 hours. For 
sample 4, about 5% of the gadolinium was released in 3 hours and less than 10% of 
the gadolinium was released in 21 hours. For both samples, there was a small initial 
burst in the first 3 hours and after that, the release rate was quite slow. This release 
profile may be favorable in MR imaging. 
However, the in vitro release profile demonstrated in PBS buffer could not accurately 
reveal the real behavior of gadolinium after the nanoparticles were administered to 
the animals. There are many proteins and molecules in the blood which may interact 





























Fig 19 Release of gadolinium from the nanoparticle further investigate the release 
profile of drug from the nanoparticles in serum.  
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CHARPTER FIVE 
CONCLUSIONS AND FUTURE WORK 
5.1 CONCLUSION 
In this study, nanoparticles of biodegradable polymer were prepared as a drug 
delivery device to cross the blood brain barrier. PLGA particles below 300 nm were 
made by single emulsion solvent evaporation method. Paclitaxel, a model drug, had 
relatively high encapsulation efficiency in the particles. The surface properties of the 
particles were modified by coating the surface with tween 80, poloxamer 188 and 
poloxamer 407 or by changing the usually used emulsifier PVA to a natural 
biomolecule, VE-TPGS. After modification, the surface charge of the particles was 
changed. More importantly, the cellular uptake of the particles in monolayer of 
MDCK cells was increased from 30% to about 50% or 60%. The internalization of 
the nanoparticles in MDCK cells were proved by confocol laser scanning microscopy. 
From the in vitro cell work it may be concluded that using nanoparticles of 
biodegradable polymers to penetrate the blood brain barrier is feasible. And the size 
and surface properties of the nanoparticles play key roles. To carry out animal studies, 
Gd-DTPA PLA-PEG nanoparticles were prepared by nanoprecipitation method. 
Nanoparticles around 100 nm were obtained. ICP-AES were employed to measure the 
amount of gadolinium in the particles. It was found the polymer played important 
roles in determining the content of gadolinium in the particles. In vivo experiment on 
rat has been designed and will be carried out. 
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5.2 FUTURE WORK 
 In this work, we have demonstrated on cell level that it is feasible to use 
nanoparticles of biodegradable polymers to cross the blood brain barrier. And the 
particles for animal study were almost ready to be used. To further investigate the 
feasibility of nanoparticles to cross the blood brain barrier and their distribution in the 
brain of the animals, animal study should be carried out by MRI. Due to the time 
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